Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer

NICE technology appraisals [TA310] Published date:

Afatinib is recommended as a possible treatment for adults with locally advanced or metastatic non-small-cell lung cancer if:

What does this mean for me?

If you have locally advanced or metastatic non-small-cell lung cancer as described above and your doctor thinks that afatinib is the right treatment, you should be able to have the treatment on the NHS.

Afatinib should be available on the NHS within 3 months of the guidance being issued.

Get involved